Joel Beatty
Stock Analyst at Baird
(4.47)
# 426
Out of 4,553 analysts
119
Total ratings
45.95%
Success rate
31.04%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Neutral | $8 → $10 | $10.47 | -4.49% | 3 | Sep 5, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $16 | $8.05 | +98.76% | 1 | Sep 4, 2024 | |
| PTCT PTC Therapeutics | Initiates: Outperform | $44 | $31.54 | +39.51% | 6 | Sep 4, 2024 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $230 → $240 | $122.60 | +95.76% | 3 | Aug 9, 2024 | |
| BPMC Blueprint Medicines | Maintains: Outperform | $112 → $127 | $86.43 | +46.94% | 2 | Aug 2, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $160 → $154 | $107.14 | +43.74% | 2 | Aug 1, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $490 → $515 | $542.00 | -4.98% | 4 | Jul 29, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Outperform | $58 | $26.62 | +117.88% | 1 | Jul 26, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $15 → $13 | $7.50 | +73.33% | 3 | Jul 25, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $37 → $38 | $26.86 | +41.47% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $60 | $34.86 | +72.12% | 2 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $6 | $2.54 | +136.22% | 4 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $54 | $35.00 | +54.29% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $55.24 | +30.34% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $5.95 | +354.16% | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $104 → $72 | $84.08 | -14.37% | 4 | May 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $1.16 | +1,631.60% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $16.07 | +74.24% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $108 → $112 | $93.19 | +20.19% | 2 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $117 | $54.02 | +116.59% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $4.25 | +5.88% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $103 | $73.54 | +40.06% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $23.33 | +7.16% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $2.37 | +26.58% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $2.81 | +220.28% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $19.10 | +46.60% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.04 | +17,400.00% | 1 | Sep 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $140 → $60 | $0.07 | +89,452.24% | 3 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $5.88 | +172.11% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.88 | +699.09% | 1 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.97 | -36.55% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $12.87 | +241.88% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $22.22 | +161.03% | 2 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $36.21 | -33.72% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $18 | $3.59 | +401.39% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $18.69 | -3.69% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.11 | +184.36% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $9.31 | +232.98% | 2 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $7.76 | +260.82% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $246.78 | - | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.02 | - | 4 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $128.92 | - | 2 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.69 | - | 1 | Jun 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $46.89 | - | 2 | Apr 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $20 | $0.80 | +2,399.69% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $0.60 | - | 3 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $0.65 | - | 1 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.65 | - | 5 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | n/a | $1.41 | - | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | n/a | $11.63 | - | 3 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $19.29 | - | 1 | Nov 10, 2017 |
Cogent Biosciences
Sep 5, 2024
Maintains: Neutral
Price Target: $8 → $10
Current: $10.47
Upside: -4.49%
Larimar Therapeutics
Sep 4, 2024
Initiates: Outperform
Price Target: $16
Current: $8.05
Upside: +98.76%
PTC Therapeutics
Sep 4, 2024
Initiates: Outperform
Price Target: $44
Current: $31.54
Upside: +39.51%
e.l.f. Beauty
Aug 9, 2024
Maintains: Outperform
Price Target: $230 → $240
Current: $122.60
Upside: +95.76%
Blueprint Medicines
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $86.43
Upside: +46.94%
Jazz Pharmaceuticals
Aug 1, 2024
Maintains: Outperform
Price Target: $160 → $154
Current: $107.14
Upside: +43.74%
argenx SE
Jul 29, 2024
Maintains: Outperform
Price Target: $490 → $515
Current: $542.00
Upside: -4.98%
Dianthus Therapeutics
Jul 26, 2024
Initiates: Outperform
Price Target: $58
Current: $26.62
Upside: +117.88%
Sage Therapeutics
Jul 25, 2024
Maintains: Neutral
Price Target: $15 → $13
Current: $7.50
Upside: +73.33%
Alkermes
Jul 25, 2024
Maintains: Outperform
Price Target: $37 → $38
Current: $26.86
Upside: +41.47%
Jul 11, 2024
Maintains: Outperform
Price Target: $36 → $60
Current: $34.86
Upside: +72.12%
Jun 27, 2024
Maintains: Outperform
Price Target: $7 → $6
Current: $2.54
Upside: +136.22%
Jun 11, 2024
Initiates: Outperform
Price Target: $54
Current: $35.00
Upside: +54.29%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $55.24
Upside: +30.34%
May 28, 2024
Initiates: Outperform
Price Target: $27
Current: $5.95
Upside: +354.16%
May 17, 2024
Downgrades: Neutral
Price Target: $104 → $72
Current: $84.08
Upside: -14.37%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $1.16
Upside: +1,631.60%
May 9, 2024
Maintains: Outperform
Price Target: $31 → $28
Current: $16.07
Upside: +74.24%
May 7, 2024
Maintains: Outperform
Price Target: $108 → $112
Current: $93.19
Upside: +20.19%
May 1, 2024
Initiates: Outperform
Price Target: $117
Current: $54.02
Upside: +116.59%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $4.25
Upside: +5.88%
Apr 17, 2024
Maintains: Outperform
Price Target: $83 → $103
Current: $73.54
Upside: +40.06%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $23.33
Upside: +7.16%
Apr 11, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $2.37
Upside: +26.58%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $2.81
Upside: +220.28%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $19.10
Upside: +46.60%
Sep 8, 2023
Initiates: Outperform
Price Target: $7
Current: $0.04
Upside: +17,400.00%
Aug 15, 2023
Maintains: Outperform
Price Target: $140 → $60
Current: $0.07
Upside: +89,452.24%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $5.88
Upside: +172.11%
May 23, 2023
Initiates: Outperform
Price Target: $7
Current: $0.88
Upside: +699.09%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.97
Upside: -36.55%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $12.87
Upside: +241.88%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $22.22
Upside: +161.03%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $36.21
Upside: -33.72%
Nov 18, 2022
Maintains: Outperform
Price Target: $25 → $18
Current: $3.59
Upside: +401.39%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $18.69
Upside: -3.69%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.11
Upside: +184.36%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $9.31
Upside: +232.98%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $7.76
Upside: +260.82%
Feb 12, 2021
Downgrades: Neutral
Price Target: n/a
Current: $246.78
Upside: -
Jan 14, 2021
Downgrades: Neutral
Price Target: n/a
Current: $5.02
Upside: -
Jan 12, 2021
Downgrades: Neutral
Price Target: n/a
Current: $128.92
Upside: -
Jun 11, 2020
Downgrades: Neutral
Price Target: n/a
Current: $0.69
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: n/a
Current: $46.89
Upside: -
Apr 6, 2020
Maintains: Buy
Price Target: $28 → $20
Current: $0.80
Upside: +2,399.69%
Apr 1, 2020
Maintains: Buy
Price Target: n/a
Current: $0.60
Upside: -
Mar 26, 2020
Maintains: Buy
Price Target: n/a
Current: $0.65
Upside: -
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $1.65
Upside: -
Aug 17, 2018
Maintains: Neutral
Price Target: n/a
Current: $1.41
Upside: -
Feb 21, 2018
Maintains: Neutral
Price Target: n/a
Current: $11.63
Upside: -
Nov 10, 2017
Maintains: Buy
Price Target: n/a
Current: $19.29
Upside: -